Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company focused on first-in-class critical care products and holds a majority interest in Citius Oncology, Inc. News about CTXR often centers on regulatory milestones, clinical progress, and financing activities that support the development and commercialization of its therapies.
Recent company communications emphasize the FDA approval of LYMPHIR (denileukin diftitox-cxdl) for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy, and the subsequent U.S. commercial launch executed by Citius Oncology. CTXR news also highlights the late-stage status of Mino-Lok, a catheter lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief, along with completed pivotal and Phase 2b trials.
Investors following CTXR can expect updates on capital raises such as registered direct offerings and warrant issuances, which the company states are intended to fund the commercial launch of LYMPHIR, regulatory and milestone payments, and broader development initiatives. Filings and press releases also describe ongoing engagement with the FDA regarding next steps for Mino-Lok and Halo-Lido.
This news feed aggregates press releases, regulatory disclosures, and other public announcements related to Citius Pharmaceuticals and its majority-owned oncology subsidiary. For those tracking CTXR, it provides a centralized view of developments across oncology, critical care, clinical trials, and corporate finance. Regular review of this page can help readers monitor how Citius Pharmaceuticals advances its portfolio and supports the commercialization of LYMPHIR through Citius Oncology.
Citius Oncology (NASDAQ:CTOR) has signed a distribution services agreement with Cencora (formerly AmerisourceBergen) for its FDA-approved immunotherapy LYMPHIR™. The agreement enhances the company's commercial infrastructure for the distribution of LYMPHIR, which treats relapsed or refractory cutaneous T-cell lymphoma (CTCL).
This partnership expands Citius Oncology's distribution network and complements a previously announced distribution agreement, strengthening the company's market reach and supporting long-term scalability. Under the agreement, Cencora will serve as a wholesale distributor for LYMPHIR, facilitating product availability across its distribution network.
Citius Pharmaceuticals (NASDAQ:CTXR) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or higher for 10 consecutive trading days from June 20, 2025 to July 3, 2025, meeting Nasdaq Listing Rule 5550(a)(2).
As a result, the previously scheduled Nasdaq Hearing Panel has been cancelled, and CTXR will continue to be listed and traded on the Nasdaq Stock Market. CEO Leonard Mazur emphasized the company's commitment to developing critical care products and creating shareholder value.
Citius Pharmaceuticals (CTXR) and its oncology subsidiary Citius Oncology (CTOR) announced their participation in the upcoming Jefferies Global Healthcare Conference in New York City from June 3-5, 2025. Chairman and CEO Leonard Mazur will deliver a presentation on Thursday, June 5, 2025, at 3:10 pm ET.
The presentation will be available via live webcast and archived for later viewing on the company's website. Additionally, Mr. Mazur will engage in one-on-one meetings with institutional investors during the conference. Interested investors can arrange meetings through their Jefferies representatives.
Citius Pharmaceuticals (NASDAQ: CTXR) has announced a $2 million registered direct offering of common stock. The company will issue 1,739,131 shares at a purchase price of $1.15 per share, with the option for pre-funded warrants. The offering, expected to close around April 2, 2025, is being facilitated by H.C. Wainwright & Co. as the exclusive placement agent.
The net proceeds, after deducting placement agent fees and offering expenses, will be used to support the commercial launch of LYMPHIR™ and general corporate purposes. The offering is being made through a shelf registration statement filed with the SEC on February 23, 2024, and declared effective on March 1, 2024.
Citius Pharmaceuticals (CTXR) reported its fiscal Q1 2025 results, highlighting preparations for the LYMPHIR commercial launch in H1 2025. The company secured a new J-code (J9161) for LYMPHIR, effective April 1, 2025, and reported promising preliminary results from an ongoing Phase I trial combining LYMPHIR with pembrolizumab.
Financial results showed cash and cash equivalents of $1.1 million as of December 31, 2024. The company reported a net loss of $10.3 million ($1.30 per share), compared to $9.2 million ($1.45 per share) in the prior year. R&D expenses decreased to $2.1 million from $2.6 million, while G&A expenses increased to $5.4 million from $3.7 million.
The company raised $6.5 million through offerings in late 2024 and early 2025, completed a 1-for-25 reverse stock split, and regained Nasdaq compliance.